Heparin-Free DALI LDL-Apheresis in Hyperlipidemic Patients: Efficacy, Safety and Biocompatibility

Background and Aim of Study In routine DALI apheresis - the first technique for direct adsorption of lipoproteins from whole blood - heparin plus citrate (ACD-A) is used as anticoagulation regimen. However, recently several publications have warned of heparin-induced thrombocytopenia as a rare but potentially life-threatening complication of heparin administration (HIT type 2). The aim of the present study was therefore to test the efficacy and biocompatibility of DALI using a heparin-free anticoagulation regimen consisting exclusively of citrate. Methods Four symptomatic hypercholesterolemic patients on regular DALI apheresis were switched to the heparin-free protocol for two sessions each. Two of the patients were on oral anticoagulation using phenprocoumon. In the weekly sessions, 1.3 patient blood volumes were processed at a blood flow rate of 60 ml/min using ACD-A at a ratio of 1:20 (v/v) during adsorber priming and the session. Results Clinically, all sessions were essentially uneventful. Uncorrected lipoprotein reductions amounted to 65% for LDL-C, 62% for Lp(a), 53% for VLDL-C, 24% for HDL-C, 17% for triglycerides and 19% for fibrinogen. Cell counts remained virtually constant. No signs of hemolysis or clotting could be detected. Thromboplastin time (Quick) was slightly prolonged and partial thromboplastin time (PTT) moderately elevated in all patients. In constrast, whole blood coagulation time acc. to Lee-White and activated clotting times were increased only in orally anticoagulated patients. Biocompatibility in terms of complement, leukocyte and thrombocyte activation was excellent. Bradykinin activation was moderate peaking at 3038 pg/ml in the efferent line. Systemic thrombin-antithrombin complex (TAT) reflected perfect anticoagulation in orally anticoagulated patients and adequate anticoagulation in the patients without phenprocoumon. Conclusion In this pilot study, heparin-free DALI apheresis was safe and effective and may thus be performed in LDL-apheresis dependent patients who suffer from heparin intolerance.

[1]  M. Toepfer,et al.  DALI apheresis in hyperlipidemic patients: biocompatibility, efficacy, and selectivity of direct adsorption of lipoproteins from whole blood. , 2000, Artificial organs.

[2]  W. Samtleben,et al.  Low density lipoprotein hemoperfusion by direct adsorption of lipoproteins from whole blood (DALI apheresis): clinical experience from a single center. , 1999, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[3]  Schaper,et al.  DALI—the first human whole‐blood low‐density lipoprotein and lipoprotein (a) apheresis system in clinical use: procedure and clinical results , 1998, European journal of clinical investigation.

[4]  W. Kleophas,et al.  LDL hemoperfusion--a new procedure for LDL apheresis: first clinical application of an LDL adsorber compatible with human whole blood. , 2008, Artificial organs.

[5]  A. Gotto,et al.  Effects of lipid lowering therapy on progression of coronary and carotid artery disease. , 1997, Current Opinion in Lipidology.

[6]  B. Gordon,et al.  Current status of low density lipoprotein-apheresis for the therapy of severe hyperlipidemia , 1996, Current Opinion in Lipidology.

[7]  T. Bosch.  Lipid apheresis: from a heroic treatment to routine clinical practice. , 1996, Artificial organs.

[8]  T. Lindhout.  Biocompatibility of extracorporeal blood treatment. Selection of haemostatic parameters. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  M. Blumenstein,et al.  Lipid apheresis by hemoperfusion: in vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood. , 2008, Artificial organs.

[10]  A. Yamamoto,et al.  Assessment of the biocompatibility and long-term effect of LDL-apheresis by dextran sulfate-cellulose column. , 2008, Artificial organs.

[11]  K. Bhoola,et al.  Bioregulation of kinins: kallikreins, kininogens, and kininases. , 1992, Pharmacological reviews.

[12]  J. Hirsh.  Drug therapy : heparin , 1991 .

[13]  J. Nordenström,et al.  Lipolytic and anticoagulant activities of a low molecular weight fragment of heparin , 1985, European journal of clinical investigation.

[14]  S. Hosoda,et al.  An improved method for the determination of human blood kinin levels by sensitive kinin radioimmunoassay. , 1982, Endocrinologia japonica.

[15]  M. Kazatchkine,et al.  Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. , 1981, The Journal of clinical investigation.